[STOCK WATCH] Daihan Pharm declines 1%

By thinkpool

Published : Oct. 25, 2016 - 10:04

- Link copied

■ Market Review

On Oct. 25, Daihan Pharm (023910) declined 1.01%, to 29,400 won (US$25.88). It had declined 3.92% through the past month. Standard deviation, which indicates variableness, records 2.1% over the same period of time over one month.

Compared with its close competitors within the same industry, KOSDAQ, Daihan Pharm was not only the most satisfactory in investment return among its peer group, but its volatility was also relatively good. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -1.8%. As low volatility and a satisfactory stock price, the return-on-risk remain the highest among its peer group. Moreover, compared with the KOSDAQ industry, the return-on-risk is much better than the industrial mean, -9.2, and thus the industrial comparison performance was good.

Comparing industry to the market, the KOSDAQ industry including Daihan Pharm records higher volatility but lower earning rate than pharmacy. Even though the earning rate of the industry is negative, the industry was more satisfactory than the market.

Earning rate (%)

Close Competitors

Target price KRW 43,000, has 46% disparate to increase compared with stock price.
Per analysts' expectations during the recent month, the average target price of Daihan Pharm is 43,000 won. The stock price is 29,400 won as of yesterday, so there is 13,600 won (46%) disparate in order to be able to increase.

■ Earnings & Valuation

DaihanPharm(023910): 2Q(Apr ~ June) of 2016 Earnings (reported at Aug. 17. 2016)

Revenue

Financial structure Overview

Compared with four close competitors with similar market capitalization within its industry, Daihan Pharm's P/B ratio, a financial ratio of a company's book value, and its P/E ratio, a price-paid ratio of annual net income, are both at the lowest level.

P/E ratio and P/B ratio

Close Compatitors ROE

■ Investor Group

Individuals and Foreigners buy, Institutions sell
While institutions have been selling Daihan Pharm during the past two trading days, foreigners have been buying for the same amount of time. As a shareholding sum by investor group for the past four weeks, foreigners have bought 49,040 shares with a maintenance of shareholding and individuals have bought 5,383 shares lessening its position. However, during the same period, institutions have sold 54,423 shares with dominant selling.

Turnover Rate and Price Range both proper
Regarding the statistics for the past month on trade volume as the total outstanding shares, the daily turnover rate of Daihan Pharm was 0.32%. And the daily volatility, the average range of rise and fall, during the same period is 4.22%.

Institution 18.82%, Foreigners 18.96%
As per the inquiry for shareholding by investor group, the major investor group is individuals with 62.2% from total outstanding shares. Foreigners and institutions each hold 18.96% and 18.82%. And as recent five-day shareholding change by investor group, individuals is the major investor group with 56.83%. Institutions hold 21.89% and foreigners hold 21.26%.

Cumulated shareholdings per investor group (1Mo)

* Other Investor groups, included as "other corporations", are considered as "Individuals".

By HeRo (hero@heraldcorp.com">hero@heraldcorp.com)

This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.

[STOCK WATCH] Daihan Pharm declines 1%

More from Headlines